Morath Benedict, Schultes Linda, Frey Otto Roman, Röhr Anka Christa, Christow Hannes, Hoppe-Tichy Torsten, Brinkmann Alexander, Chiriac Ute
Hospital Pharmacy, Heidelberg University Hospital, Heidelberg, Germany; and.
Hospital Pharmacy, General Hospital Heidenheim, Heidenheim, Germany; and.
Ther Drug Monit. 2025 Jun 1;47(3):370-377. doi: 10.1097/FTD.0000000000001253. Epub 2024 Sep 18.
Ampicillin/sulbactam, a combination of a β-lactam and β-lactamase inhibitor, is widely used in clinical settings. However, therapeutic drug monitoring (TDM) of ampicillin is not commonly performed, particularly in intensive care units (ICUs). The purpose of this study was to develop and validate a rapid and cost-effective high-performance liquid chromatography (HPLC)-ultraviolet spectrometry method to quantify ampicillin in human serum and evaluate its clinical application in ICU patients.
Sample cleanup included a protein precipitation protocol, followed by chromatographic separation on a C18 reverse-phase HPLC column within 12.5 minutes using gradient elution of the mobile phase. The assay was validated according to the German Society of Toxicology and Forensic Chemistry criteria. Clinical applications involved the retrospective analysis of TDM data from ICU patients receiving continuous infusion of ampicillin/sulbactam, including the attainment of target ranges and individual predicted and observed pharmacokinetics.
The method was robust, with linear relations between the peak area responses and drug concentrations in the range of 2-128 mg/L. The coefficient of variation for precision and the bias for accuracy (both interday and intraday) were less than 10%. Clinical application revealed variable pharmacokinetics of ampicillin in ICU patients (clearance of 0.5-31.2 L/h). TDM-guided dose adjustments achieved good therapeutic drug exposure, with 92.9% of the samples being within the optimal (16-32 mg/L) or quasioptimal (8-48 mg/L) range.
This method provides a practical solution for the routine TDM of ampicillin, facilitating individualized dosing strategies to ensure adequate therapeutic drug exposure. Given its simplicity, cost-effectiveness, and clinical relevance, HPLC-ultraviolet spectrometry holds promise for broad implementation in hospital pharmacies and clinical laboratories.
氨苄西林/舒巴坦是一种β-内酰胺类与β-内酰胺酶抑制剂的组合,在临床环境中广泛使用。然而,氨苄西林的治疗药物监测(TDM)并不常用,尤其是在重症监护病房(ICU)。本研究的目的是开发并验证一种快速且经济高效的高效液相色谱(HPLC)-紫外光谱法,用于定量测定人血清中的氨苄西林,并评估其在ICU患者中的临床应用。
样品净化包括蛋白质沉淀步骤,随后在C18反相HPLC柱上进行色谱分离,在12.5分钟内使用流动相梯度洗脱。该测定方法根据德国毒理学和法医化学学会的标准进行验证。临床应用涉及对接受持续输注氨苄西林/舒巴坦的ICU患者的TDM数据进行回顾性分析,包括目标范围的达成以及个体预测和观察到的药代动力学。
该方法稳健,峰面积响应与2 - 128 mg/L范围内的药物浓度呈线性关系。精密度的变异系数和准确度的偏差(日间和日内)均小于10%。临床应用显示ICU患者中氨苄西林的药代动力学存在差异(清除率为0.5 - 31.2 L/h)。TDM指导的剂量调整实现了良好的治疗药物暴露,92.9%的样本处于最佳(16 - 32 mg/L)或准最佳(8 - 48 mg/L)范围内。
该方法为氨苄西林的常规TDM提供了一种实用解决方案,有助于制定个体化给药策略以确保足够的治疗药物暴露。鉴于其简单性、成本效益和临床相关性,HPLC - 紫外光谱法有望在医院药房和临床实验室中广泛应用。